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Abstract
Background: The frequencies of apolipoprotein L1 (APOL1) variants and their associations with chronic kidney
disease (CKD) vary substantially in populations from Africa. Moreover, available studies have used very small sample
sizes to provide reliable estimates of the frequencies of these variants in the general population. We determined
the frequency of the two APOL1 risk alleles (G1 and G2) and investigated their association with renal traits in a
relatively large sample of mixed-ancestry South Africans. APOL1 risk variants (G1: rs60910145 and rs73885319; G2:
rs71785313) were genotyped in 859 African mixed ancestry individuals using allele-specific TaqMan technology.
Glomerular filtration rate (eGFR) was estimated using the Modification of Diet in Renal Disease (MDRD) and
Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations.
Results: The frequencies of rs73885319, rs60910145 and rs71785313 risk alleles were respectively, 3.6 %, 3.4 %, and
5.8 %, resulting in a 1.01 % frequency of the APOL1 two-risk allele (G1:G1 or G1:G2 or G2:G2). The presence of the
two-risk allele increased serum creatinine with a corresponding reduction in eGFR (either MDRD or CKD-EPI based).
In dominant and log-additive genetic models, significant associations were found between rs71785313 and systolic
blood pressure (both p ≤ 0.025), with a significant statistical interaction by diabetes status, p = 0.022, reflecting a
negative non-significant effect in nondiabetics and a positive effect in diabetics.
Conclusions: Although the APOL1 variants are not common in the mixed ancestry population of South Africa, the
study does provide an indication that APOL1 variants may play a role in conferring an increased risk for renal and
cardiovascular risk in this population.
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Background
In 2008, through admixture-mapping linkage-
disequilibrium genome scan, two landmark studies
identified a risk locus on chromosome 22q12.3 which
explained the increased burden of nondiabetic endstage
renal disease (ESRD) and focal segmental glomerulo-
sclerosis (FSGS) in individuals of recent African ances-
try [1, 2]. These studies provided evidence that genetic
variation on the myosin9 gene (MYH9) conferred most
or nearly all of the increased risk for nondiabetic kidney
disease in African Americans [1, 2]. However, subsequent
reanalysis of chromosome 22q12.3 region utilizing the
1000 Genome Project, identified genetic variants in the
apolipoprotein L1 gene (APOL1) which extended beyond
MYH9 [3, 4]. These are located 14kbp downstream from
the 3’end of MYH9 and the strongest significant associ-
ation with ESRD was found in a 10-kb region in the last
exon of APOL1 [3, 4]. Of the single nucleotide polymor-
phisms (SNPs) identified, two were nonsynonymous
(rs73885139 and rs60910145) designated G1, and one a 6-
bp deletion (rs71785313) termed G2. The two missense
variants are in almost absolute linkage disequilibrium
while the G2 is in complete negative linkage disequilib-
rium with G1.
The APOL1 is known for its lytic effects on trypano-
somes, which cause sleeping sickness in humans [5].
However, one of the Tryanosoma species (T. brucei
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rhodesiense) overcomes the lytic effects of APOL1 by ex-
pressing a serum resistance-associated protein (SRA) [6].
The presence of G1 and G2 polymorphisms in the SRA
binding domain are believed to restore the APOL1
ability to kill T. brucei rhodesiense [7], hence the positive
selection of the variants in endemic regions, particularly
in sub-Saharan Africa. Variation in frequency is substan-
tial within Africa; and therefore the contribution to
chronic kidney disease (CKD) is likely to vary [4, 7].
However, at this time the geographic variation in APOL1
association with CKD is unknown, since it has not yet
been tested. Therefore, herein, we sought to determine
the frequency of APOL1 variants and their association
with CKD traits in a South African population with an
African ancestry, high prevalence of CKD and poor car-
diovascular risk profile.
Results
Two hundred and thirty nine (27.8 %) participants had
diabetes and their general characteristics are summa-
rized in Table 1. The overall mean age was 53.1 years,
with significant differences between those with and
without diabetes (51.0 vs. 58.7 years, p < 0.0001). The
eGFR was significantly lower in individuals with diabetes
compared to those without diabetes as well as in women
vs. men (all p < 0.0001), whilst systolic blood pressure
and diastolic blood pressure were significantly elevated
in men (both p ≤ 0.016).
The frequency distributions, both genotype and allele,
did not differ significantly according to gender and
diabetes status. Deletion of the sequence TTATTA of
rs71785313 was borderline more frequent in women
than in men (6.3 % vs. 3.8 %, p = 0.065), (Table 2). The
concomitance of two-risk alleles was observed in 9 indi-
viduals (1.01 %) whilst 143 (16.6 %) had one-risk allele
(Table 3). In participants with two-risk alleles, serum
creatinine was elevated with a corresponding reduction
of eGFR (either MDRD or CKD-EPI based) than in those
with only one-risk allele or none, but differences did not
reach statistical significance. Furthermore, these were
still more likely to have higher prevalence of hyperten-
sion (Table 3).
In a recessive model adjusted for age, sex, diabetes
status and hypertension, the G1 risk alleles showed a
borderline association with prevalent CKD (CKD-EPI),
p = 0.047 (Table 4). On the other hand, in generalized
linear and logistics regression models (dominant and log-
additive genetic models) adjusted for age, sex, diabetes
Table 1 Baseline characteristics by diabetes status and gender
Characteristics No diabetes Diabetes p-value Men Women p-value Overall
N 620 239 195 664 859
Gender, men n (%) 140 (22.6) 55 (23.0) 0.892 195 (100) - NA 195 (22.7)
Mean age, years (SD) 51.0 (13.9) 58.7 (12.9) <0.0001 54.5 (14.6) 52.7 (13.9) 0.140 53.1 (14.1)
Mean BMI, kg/m2 (SD) 29.4 (7.2) 31.7 (7.4) <0.0001 26.4 (6.4) 31.1 (7.2) <0.0001 30.0 (7.3)
Mean WHR (SD) 0.87 (0.10) 0.92 (0.09) <0.0001 0.93 (0.08) 0.87 (0.10) <0.0001 0.88 (0.10)
Mean SBP, mmHg (SD) 121 (19) 130 (23) <0.0001 127 (19) 123 (21) 0.016 124 (21)
Mean DBP, mmHg (SD) 75 (12) 76 (13) 0.073 77 (12) 76 (13) 0.006 75 (12)
Hypertension, yes (%) 336 (54.2) 156 (65.3) 0.003 94 (48.2) 398 (59.9) 0.004 492 (57.3)
Mean HbA1c, % (SD) 5.7 (0.4) 7.8 (2.1) <0.0001 6.3 (1.7) 6.3 (1.4) 0.901 6.3 (1.5)
Mean FBG, mmol/l (SD) 5.2 (0.7) 9.8 (4.3) <0.0001 6.4 (3.5) 6.4 (3.0) 0.928 6.4 (3.1)
Mean 2-h glucose, mmol/l (SD) 6.5 (1.6) 13.3 (5.0) <0.0001 6.9 (3.0) 7.8 (3.7) 0.004 7.6 (3.5)
Median urine creatinine, mmol/l
(25th-75th percentiles)
8.1 [5.3-12.2] 7.0 [4.3-11.3 0.045 10.3 [5.9-14.3] 7.3 [5.0-11.2] <0.0001 7.9 [5.2-11.9]
Median urine Microalbumin, mg/l
(25th-75th percentiles)
3.7 [3.0-9.5] 7.6 [3.0-28.9] <0.0001 5.7 [3.0-14.9] 4.1 [3.0-10.4] 0.093 4.4 [3.0-11.3]
Median ACR, mg/mmol (25th-75th
percentiles)
0.62 [0.37-1.25] 1.06 [0.59-3.27] <0.0001 0.67 [0.32-1.79] 0.77 [0.45-1.54] 0.123 0.75 [0.41-1.57]
Median serum creatinine,μmol/l
(25th-75th percentiles)
79 [69-90] 82 [70-97] 0.016 92 [82-102] 77 [67-88] <0.0001 80 [69-92]
Median eGFR (MDRD), ml/min (SD) 87.8 [73.7-101.9] 79.6 [66.6-96.3] <0.0001 91.6 [77.5-105.8] 84.0 [69.9-98.9] 0.0001 85.8 [71.1-100.7
eGFR (MDRD) <60, n (%) 43 (6.9) 36 (15.1) 0.0002 13 (6.7) 66 (9.9) 0.164 79 (9.2)
Median eGFR (CKD-EPI), ml/min (SD) 94.9 [77.5-110.1] 82.8 [67.8-103.1] <0.0001 96.5 [78.2-111.6] 90.0 [71.9-107.5] 0.033 91.2 [72.8-108.8]
eGFR (CKD-EPI) <60, n (%) 39 (6.3) 34 (14.2) 0.0002 14 (7.2) 59 (8.9) 0.453 73 (8.5)
ACR, urinary albumin/creatinine ratio; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; eGFR, estimated glomerular filtration rate; MDRD, Modification
of Diet in Renal Disease; SD, standard deviation
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status and hypertension, none of the genotypes was asso-
ciated with serum creatinine, urinary albumin/creatinine
ratio or prevalent CKD (Table 5 and 6). These genetic
models revealed an association between G2 (rs71785313)
and systolic blood pressure (both p ≤ 0.025), with a signifi-
cant statistical interaction by diabetes status, p = 0.025,
reflecting a negative non-significant effect in nondiabetics
and a positive effect in diabetics.
Discussion
This study aimed to determine the frequency of the two
APOL1 risk alleles (G1 and G2) and their association
with renal traits in a general South African mixed
ancestry population. The findings from this study show
that 16.6 % of the participants carried at least one
APOL1 risk allele. The G1 risk alleles, rs73885319 and
rs60910145 were observed respectively in, 3.6 %, 3.4 %
of individuals whilst G2 risk allele carriers were 5.8 %,
resulting in a 1.01 % frequency of the APOL1 two-risk
allele (G1:G1 or G1:G2 or G2:G2). The presence of two-
risk alleles decreased eGFR and the G1 risk alleles
showed a borderline association with prevalent CKD
(CKD-EPI), p = 0.047. On one hand, the G2 leaned to-
wards an association with systolic blood pressure (p ≤
0.025), with a significant statistical interaction by dia-
betes status, p = 0.025 assuming either dominant or log-
additive. Our findings in the context of a small sample
could also reflect the inadequate statistical power for
uncovering some significant associations.
The strong association between APOL1 and non-
diabetic kidney diseases has been replicated in several
studies [8–11] since the initial observations reported in
African Americans with hypertensive kidney disease and
FSGS [3, 4]. This risk is mostly conferred by the pres-
ence of two copies of the risk alleles, that is, homozy-
gous or compound heterozygous compared to no or one
APOL1 risk variant [3, 4]. In our study, the frequency of
the two-risk allele was much lower than that reported in
African Americans (13 %) [12], and it was borderline
associated with CKD or its markers. Furthermore, car-
riers of the two-risk allele were more likely to have
hypertension. Our findings may be attributed to the
non-discriminatory nature of our study in which diabetic
and non-diabetic kidney diseases were not analyzed sep-
arately and would have resulted in an even smaller num-
ber of CKD cases. Nevertheless, our study does provide
an indication that APOL1 variants may play a role in
conferring a poor renal disease and cardiovascular risk
profile in this population. In linear genetic regression
models, the G2 risk allele was significantly associated
with systolic blood pressure. Emerging data point to an
expanding role of APOL1 genetic aberrations implying
that they are not limited to kidney diseases, but are also
associated with increased risk of cardiovascular disease
Table 2 Genotype distributions, minor allele frequencies, and unadjusted p-values for comparing genotype distributions according
to diabetes status and gender
No diabetes Diabetes p-value Men Women p-value Overall
N 620 239 195 664 859
rs60910145
T/T, n (%) 582 (93.9) 220 (92.0) 0.355 179 (91.8) 623 (93.8) 0.380 802 (93.4)
T/G, n (%) 36 (5.8) 19 (7.9) 16 (8.2) 39 (5.9) 55 (6.4)
G/G, n (%) 2 (0.3) 0 (0) 0 (0) 2 (0.3) 2 (0.2)
G, n (%) 40 (3.2) 19 (4.0) 0.446 16 (4.1) 43 (3.2) 0.410 59 (3.4)
HWE (p-value) 0.127 >0.999 >0.999 0.145 0.263
rs73885319
A/A, n (%) 580 (93.5) 219 (91.6) 0.346 179 (91.8) 620 (93.4) 0.492 799 (93.0)
A/G, n (%) 38 (6.1) 20 (8.4) 16 (8.2) 42 (6.3) 58 (6.7)
G/G, n (%) 2 (0.3) 0 (0) 0 (0) 2 (0.3) 2 (0.2)
G, n (%) 42 (3.4) 20 (4.2) 0.427 16 (4.1) 46 (3.5) 0.554 62 (3.6)
HWE (p-value) 0.150 >0.999 >0.999 0.181 0.302
rs71785313
TTATTA / TTATTA, n (%) 555 (89.5) 210 (87.9) 0.704 181 (92.8) 584 (87.9) 0.154 765 (89.1)
TTATTA /Del, n (%) 62 (10.0) 27 (11.3) 13 (6.7) 76 (11.4) 89 (10.4)
Del/Del, n (%) 3 (0.5) 2 (0.8) 1 (0.5) 4 (0.6) 5 (0.6)
Del, n (%) 68 (11.0) 31 (6.5) 0.424 15 (3.8) 84 (6.3) 0.065 99 (5.8)
HWE (p-value) 0.420 0.253 0.244 0.324 0.195
HWE, Hardy-Weinberg Equilibrium (HWE p-values are from exact tests)
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(CVD) [13]. In two cohorts, the Jackson Heart Study
(JHS) and the Women’s Health Initiative (WHI), the
APOL1 two-risk allele increased by two-fold the risk for
myocardial infarction, stroke, and therapeutic surgical or
endovascular interventions in African Americans [13].
Furthermore, APOL1 G2 homozygous individuals were
shown to be at an increased risk for stroke compared to
G1 two risk alleles [13].
Although the link between hypertension and CKD is
well established, CKD progression is augmented in
African Americans compared to their Caucasian coun-
terparts with similar blood pressure control [14, 15].
The APOL1 risk variants have recently been suggested
to be the missing link in the accelerated progression of
hypertensive CKD despite adequate blood pressure con-
trol in African Americans [16]. In the African American
Study of Kidney Disease and Hypertension comprising
693 black patients with hypertensive CKD, Parsa et al.
[16] used a codominant genetic model to show that
patients with the APOL1 two-risk allele had a 2-fold risk
of doubling their serum creatinine from baseline or
developing incident end-stage renal disease over a 9-year
period of follow-up. Furthermore, the progression of
CKD in these patients was independent of blood pres-
sure control [16]. The mechanism by which APOL1 risk
variants contribute to the pathogenesis of hypertensive
CKD has not been elucidated. Several possible mecha-
nisms have been suggested including a role in lipid
metabolism since APOL1 is mainly bound to high dens-
ity lipoprotein [17], and variations in APOL1 circulating
levels have been associated with its genetic variants [18,
19]. Another hypothesis relates to the localization of
APOL1 protein in kidney vascular endothelium [20, 21].
In view of these studies including ours, a functional role
of APOL1 in vasculorpathology, hypertension and kidney
disease is worth exploring.
The predominance of APOL1 variants in Africans and
populations with an African ancestry is linked to a
natural selection, as they protect against trypanosomal
infection [5] from a species that is endemic in certain re-
gions of Africa [22]. Another factor is the differing risk
of non-diabetic kidney diseases. One example is a study
conducted in an Ethiopian population without HIV-
associated nephropathy, which showed an absence of the
APOL1 G1 and G2 risk alleles [4, 23]. In comparison
with other populations from Africa, the frequencies of
APOL1 risk alleles are relatively similar [4, 8] except
those in Western African populations [4, 9–11]. Since
the Cape region of South Africa is far south of the tsetse
fly belt, the moderate frequency of the APOL1 risk al-
leles is likely due to the African ancestry reported in this
population [24].
Table 3 Baseline characteristics by allele combination
Characteristics 0 risk allele One risk allele Two risk alleles P-value* p-value**
N 707 143 9
Gender, men n (%) 166 (23.5) 27 (18.8) 2 (22.2) 0.488 0.972
Mean age, years (SD) 53.2 (14.0) 52.7 (10.0) 54.3 (10.2) 0.902 0.797
Mean BMI, kg/m2 (SD) 30.0 (7.5) 30.0 (6.7) 32.0 (6.9) 0.722 0.420
Mean WHR (SD) 0.88 (0.10) 0.89 (0.08) 0.92 (0.11) 0.484 0.266
Mean SBP, mmHg (SD) 123 (20) 127 (23) 121 (12) 0.113 0.737
Mean DBP, mmHg (SD) 75 (12) 77 (13) 75 (12) 0.117 0.884
Hypertension, yes (%) 466 (65.9) 98 (68.5) 8 (88.9) 0.301 0.118
Mean HbA1c, % (SD) 6.2 (1.4) 6.5 (1.7) 6.6 (1.5) 0.154 0.586
Mean FBG, mmol/l (SD) 6.3 (3.0) 6.9 (3.6) 7.0 (3.3) 0.140 0.599
Mean 2-h glucose, mmol/l (SD) 7.4 (3.2) 8.2 (4.7) 9.0 (4.2) 0.040 0.264
Median urine creatinine, mmol/l (25th-75th percentiles) 7.9 [5.2-11.8] 7.9 [4.5-12.1] 5.6 [5.5-8.8] 0.664 0.466
Median urine Microalbumin, mg/l (25th-75th percentiles) 4.4 [3.0-11.4] 4.3 [3.0-11.7] 3.0 [3.0-7.3] 0.537 0.293
Median ACR, mg/mmol (25th-75th percentiles) 0.75 [0.41-1.61] 0.77 [0.41-1.50] 0.54 [0.34-1.06] 0.876 0.541
Median serum creatinine,μmol/l (25th-75th percentiles) 80 [69-92] 79 [69-90] 85 [82-92] 0.254 0.244
Median eGFR (MDRD), ml/min (SD) 85.9 [70.8-102.2] 84.2 [73.9-99.1] 76.6 [73.6-81.0] 0.258 0.147
eGFR (MDRD) <60, n (%) 67 (9.5) 11 (7.7) 1 (11.1) 0.781 0.846
Median eGFR (CKD-EPI), ml/min (SD) 91.8 [72.0-109.9] 91.2 [75.2-107.9] 82.2 [77.1-85.2] 0.275 0.160
eGFR (CKD-EPI) <60, n (%) 60 (8.5) 12 (8.4) 1 (11.1) 0.960 0.786
ACR, urinary albumin/creatinine ratio; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; eGFR, estimated glomerular filtration rate; MDRD, Modification
of Diet in Renal Disease; SD, standard deviation
*p-values from chi square, ANOVA and Kruskal-Wallis tests
**p-values from recessive genetic models
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There are some limitations to be accounted for in the
interpretation of our findings. These include a low num-
ber of participants with advanced stage CKD, in spite of
our large sample, which may have resulted in a reduced
statistical power to uncover significant associations. Al-
though other studies from Africa did include patients
with advanced CKD, and were consequently adequately
powered to capture significant effects of genes on the
disease risk, these studies have however used small sam-
ple sizes to provide reliable estimates of the frequencies
of those gene variants in the general population as we
have done. Our study comprised participants with CKD
of various etiologies that could have been either diabetic
or non-diabetic. Findings could therefore be different if
the study was based on a population with a more
homogenous type of CKD. Our study was also limited
by the heterogeneous nature of the study population,
which is of mixed genetic origin with contributions from
Europeans, South Asians, Indonesians and a population
genetically close to the isiXhosa sub-Saharan Bantu [24],
necessitating the use of ancestry informative markers to
account for population stratification. Potential population
stratification in an unrelated sample is known to cause
spurious positive or negative associations in population-
based association studies if not accounted for. However,
due to financial constraints, this analysis was not con-
ducted, raising the possibility that population admixture
interfered with the association analysis. The renal disease
markers were based on a single measurement in a cross-
sectional study design. The cross-sectional nature of our
study precludes drawing causal inferences on the direction
of the associations.
Conclusion
In conclusion, our study provides evidence that genetic
variants in APOL1 are present in a mixed-ancestry South
African population, but their association with renal
diseases needs further exploration in patients with non-
diabetic kidney diseases.
Material and methods
Study participants and procedures
This investigation is based on the Bellville South cohort
from Cape town, South Africa that has received study
Table 4 Generalized linear and logistic regression models showing the effects of genes on kidney functions and other continuous
predictors (recessive model)
Overall
Allele Phenotype Effects size (95 % CI) P
rs60910145 G/G Serum creatinine (loge[μmol/l]) 0.192 (-0.094 to 0.478) 0.289
eGFR (MDRD) [ml/min] −18.54 (-48.59 to 11.51) 0.227
eGFR (CKD-EPI) [ml/min] −18.90 (-43.76 to 5.96) 0.136
Prevalent CKD (MDRD) 23.47 (0.92 to 599.29) 0.074
Prevalent CKD (CKD-EPI) 42.72 (1.22 to ∞) 0.047
Albumin/creatinine ratio (loge[mg/mmol]) −1.02 (-2.62 to 0.57) 0.210
Systolic blood pressure (mmHg) −0.36 (-27.67 to 26.74) 0.979
rs73885319 G/G Serum creatinine (loge[μmol/l]) 0.191 (-0.094 to 0.478) 0.189
eGFR (MDRD) [ml/min] −18.54 (-48.59 to 11.51) 0.227
eGFR (CKD-EPI) [ml/min] −18.90 (-43.76 to 5.96) 0.136
Prevalent CKD (MDRD) 23.47 (0.92 to 599.29) 0.074
Prevalent CKD (CKD-EPI) 42.72 (1.22 to ∞) 0.047
Albumin/creatinine ratio (loge[mg/mmol]) −1.02 (-2.62 to 0.57) 0.210
Systolic blood pressure (mmHg) −0.36 (-27.67 to 26.94) 0.979
rs71785313 Del/Del Serum creatinine (loge[μmol/l]) 0.038 (-0.144 to 0.219) 0.684
eGFR (MDRD) [ml/min] −7.16 (-26.19 to 11.87) 0.461
eGFR (CKD-EPI) [ml/min] −5.99 (-21.74 to 9.76) 0.456
Prevalent CKD (MDRD) 0.0 -
Prevalent CKD (CKD-EPI) 0.0 -
Albumin/creatinine ratio (loge[mg/mmol]) −0.123 (-1.134 to 0.888) 0.811
Systolic blood pressure (mmHg) −6.27 (-23.55 to 11.02) 0.478
Models are adjusted for age, sex, diabetes status and hypertension
Effect estimates are mean difference and 95 % confidence intervals for quantitative traits and odds ratio and 95 % confidence intervals for qualitative traits
CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; eGFR, estimated glomerular filtration rate; MDRD, Modification of Diet in Renal Disease
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approval from the Research Ethics Committee of the Cape
Peninsula University of Technology, Faculty of Health and
Wellness Sciences (Reference Number: CPUT/HW-REC
2008/002 and CPUT/HW-REC 2010). The study was
conducted according to the Code of Ethics of the World
Medical Association (Declaration of Helsinki) [25]. All
participants signed written informed consent after all the
procedures had been fully explained in the language of
their choice. Of the 946 self-reported mixed ancestry par-
ticipants who took part in the survey, 941 consented for
genetic studies. Among the latter, 72 were excluded for
missing data on the genetic or renal trait variables. There-
fore, 859 had valid data for the current analyses. All par-
ticipants received a standardized interview and physical
examination during which blood pressure was measured
according to the World Health Organisation (WHO)
guidelines [26] using a semi-automated digital blood pres-
sure monitor (Rossmax PA, USA) on the right arm in a
sitting position. Anthropometric measurements were per-
formed three times and their average used for analysis:
weight (kg), height (cm), waist (cm) and hip (cm)
circumferences. Participants with no history of doctor-
diagnosed diabetes mellitus underwent a 75 g oral glucose
tolerance test (OGTT) as recommended by the WHO
[27]. Further, the following biochemical parameters were
determined on the Cobas 6000 Clinical Chemistry in-
strument (Roche Diagnostics, Germany): fasting plasma
glucose, insulin, creatinine, total cholesterol (TC), high
density lipoprotein cholesterol (HDL-c), triglycerides
(TG), C-reactive protein (CRP), γ-glutamyltransferase
(GGT), and glycated haemoglobin (HbA1c) certified by
National Glycohaemoglobin Standardisation Programme
(NGSP). Low density lipoprotein cholesterol (LDL-c) was
calculated using Friedewald’s formula [28]. Urine albumin
was determined by the immunoturbidimetric assay (Cobas
6000, Roche Diagnostics, Germany).
SNP genotyping
Genomic DNA was extracted from whole blood samples
collected in an EDTA tube. The APOL1 single nucleo-
tide polymorphisms (SNPs) termed G1 (rs73885319;
rs60919145) and G2 (rs71785313) were genotyped using
Table 5 Generalized linear and logistic regression models showing the effects of genes on kidney functions and other continuous
predictors (dominant model)
Overall Interaction p for the gene and
Allele Phenotype Effects size (95 % CI) P Sex diabetes hypertension
rs60910145 T/G-G/G Serum creatinine (loge[μmol/l]) −0.029 (-0.084 to 0.026) 0.307 0.658 0.176 0.158
eGFR (MDRD) [ml/min] 2.09 (-3.73 to 7.91) 0.482 0.444 0.199 0.101
eGFR (CKD-EPI) [ml/min] 3.24 (-1.57 to 8.06) 0.187 0.768 0.143 0.103
Prevalent CKD (MDRD) 0.59 (0.18 to 1.89) 0.350 0.677 0.081 0.410
Prevalent CKD (CKD-EPI) 0.84 (0.27 to 2.65) 0.767 0.244 0.118 0.456
Albumin/creatinine ratio (loge[mg/mmol]) −0.154 (-0.502 to 0.193) 0.384 0.331 0.947 0.525
Systolic blood pressure (mmHg) −0.02 (-5.31 to 5.27) 0.993 0.839 0.536 0.963
rs73885319 A/G-G/G Serum creatinine (loge[μmol/l]) −0.026 (-0.080 to 0.028) 0.341 0.612 0.260 0.273
eGFR (MDRD) [ml/min] 1.75 (-3.93 to 7.44) 0.546 0.402 0.283 0.181
eGFR (CKD-EPI) [ml/min] 2.96 (-1.74 to 7.66) 0.217 0.708 0.233 0.264
Prevalent CKD (MDRD) 0.56 (0.18 to 1.79) 0.307 0.654 0.086 0.411
Prevalent CKD (CKD-EPI) 0.81 (0.26 to 2.54) 0.720 0.233 0.123 0.455
Albumin/creatinine ratio (loge[mg/mmol]) −0.096 (-0.436 to 0.245) 0.583 0.240 0.883 0.411
Systolic blood pressure (mmHg) −0.020 (-5.18 to 5.14) 0.994 0.834 0.585 0.837
rs71785313 TTATTA /Del-Del/Del Serum creatinine (loge[μmol/l]) 0.020 (-0.024 to 0.064) 0.382 0.549 0.801 0.891
eGFR (MDRD) [ml/min] −2.35 (-6.99 to 2.30) 0.323 0.479 0.865 0.893
eGFR (CKD-EPI) [ml/min] −3.03 (-6.88 to 0.81) 0.123 0.478 0.815 0.988
Prevalent CKD (MDRD) 0.91 (0.38 to 2.14) 0.823 0.934 0.639 0.782
Prevalent CKD (CKD-EPI) 1.07 (0.43 to 2.66) 0.890 0.971 0.487 0.622
Albumin/creatinine ratio (loge[mg/mmol]) 0.050 (-0.214 to 0.314) 0.710 0.587 0.854 0.889
Systolic blood pressure (mmHg) 5.60 (1.39 to 9.80) 0.009 0.892 0.025 0.593
Models are adjusted for age, sex, diabetes status and hypertension
Effect estimates are mean difference and 95 % confidence intervals for quantitative traits and odds ratio and 95 % confidence intervals for qualitative traits
CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; eGFR, estimated glomerular filtration rate; MDRD, Modification of Diet in Renal Disease
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high throughput real-time polymerase chain reaction
(RT-PCR) on the BioRad Optica (BioRad, USA) platform
using Taqman genotyping assay (Applied Biosystems,
USA). Conventional polymerase chain reaction followed
by direct DNA sequencing was performed for analytical
validation of high throughput genotyping.
Definitions and calculations
Body mass index (BMI) was calculated as weight per
square meter (kg/m2) and waist-hip-ratio (WHR) as
waist/hip circumferences (cm). Type 2 diabetes status was
based on a history of doctor-diagnosis, a fasting plasma
glucose ≥7.0 mmol/l and/or a 2-hour post-OGTT plasma
glucose ≥11.1 mmol/l. Hypertension was based on a his-
tory of doctor diagnosed hypertension and/or receiving
medications for hypertension or average systolic blood
pressure ≥140 mmHg and/or average diastolic blood pres-
sure ≥90 mmHg. Urinary albumin excretion was quanti-
fied in term of urinary albumin/creatinine ratio (ACR).
Glomerular filtration rate (GFR) was estimated by the 4-
variable Modification of Diet in Renal Disease (MDRD)
equation applicable to standardised serum creatinine
values [29, 30], and the Chronic Kidney Disease Epidemi-
ology Collaboration (CKD-EPI) equation [31].
Statistical analysis
General characteristics of the study group are summa-
rized as count and percentage for dichotomous traits,
mean and standard deviation (SD) or median and 25th-
75th percentiles for quantitative traits. Traits were log-
transformed to approximate normality, where necessary,
prior to analysis. SNPs were tested for departure from
Hardy-Weinberg Equilibrium (HWE) expectation via a
chi square goodness of fit test. Linkage disequilibrium
(LD) was estimated using the D’ statistic. Linear regres-
sion models were used for the analysis of quantitative
traits and logistic regression models for dichotomous
traits, assuming both dominant and log-additive genetic
models for the SNPs. Using linear and logistic models
enabled us to adjust all analyses for known confounders
as specified everywhere in the results. We investigated
the association of each SNP with each trait, overall and
tested for heterogeneity by major subgroups by adding
the interaction term of major grouping variables and
Table 6 Generalized linear and logistic regression models showing the effects of genes on kidney functions and other continuous
predictors (additive model)
Overall
Allele Phenotype Effects size (95%CI) P
rs60910145 G Serum creatinine (loge[μmol/l]) −0.020 (-0.072 to 0.033) 0.466
eGFR (MDRD) [ml/min] 1.26 (-4.27 to 6.79) 0.656
eGFR (CKD-EPI) [ml/min] 2.28 (-2.29 to 6.86) 0.328
Prevalent CKD (MDRD) 0.80 (0.28 to 2.27) 0.665
Prevalent CKD (CKD-EPI) 1.12 (0.39 to 3.16) 0.836
Albumin/creatinine ratio (loge[mg/mmol]) −0.178 (-0.504 to 0.147) 0.283
Systolic blood pressure (mmHg) −0.03 (-5.06 to 4.99) 0.989
rs73885319 G Serum creatinine (loge[μmol/l]) −0.018 (-0.069 to 0.034) 0.503
eGFR (MDRD) [ml/min] 0.99 (-4.42 to 6.40) 0.720
eGFR (CKD-EPI) [ml/min] 2.07 (-2.40 to 6.55) 0.364
Prevalent CKD (MDRD) 0.76 (0.27 to 2.16) 0.601
Prevalent CKD (CKD-EPI) 1.08 (0.38 to 3.03) 0.887
Albumin/creatinine ratio (loge[mg/mmol]) −0.126 (-0.446 to 0.195) 0.442
Systolic blood pressure (mmHg) −0.03 (-4.95 to 4.89) 0.990
rs71785313 Del Serum creatinine (loge[μmol/l]) 0.019 (-0.022 to 0.060) 0.367
eGFR (MDRD) [ml/min] −2.38 (-6.68 to 1.93) 0.323
eGFR (CKD-EPI) [ml/min] −2.91 (-6.46 to 0.65) 0.110
Prevalent CKD (MDRD) 0.86 (0.39 8to 1.93) 0.712
Prevalent CKD (CKD-EPI) 1.00 (0.42 to 2.34) 0.993
Albumin/creatinine ratio (loge[mg/mmol]) 0.035 (-0.207 to 0.277) 0.777
Systolic blood pressure (mmHg) 4.48 (0.58 to 8.38) 0.025
Models are adjusted for age, sex, diabetes status and hypertension
Effect estimates are mean difference and 95 % confidence intervals for quantitative traits and odds ratio and 95 % confidence intervals for qualitative traits.
CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; eGFR, estimated glomerular filtration rate; MDRD, Modification of Diet in Renal Disease
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each SNP to a model that contained the main effects of
grouping variable and the relevant SNP. Results corre-
sponding to p-values below 5 % are described as signifi-
cant. Adjustment for multiple testing was conducted via
Bonferroni methods. All analyses used the R statistical
software (version 3.0.3 [2014-03-06], The R Foundation
for statistical computing, Vienna, Austria) and the pack-
ages ‘genetics’ and ‘SNPassoc’.
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